Targets › IL2R
1 program from 1 company in 1 trial: 1 Phase 2; Oncology; next expected readout Nov 2027.
Open in Phaseline: the race on IL2R, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| The First Affiliated Hospital of Xiamen University | Recombinant Human Interleukin-2 Injections IL-2 receptor agonist | IL2R | Phase 2 | Hematological Malignancy | Nov 2027 |
Hematological Malignancy (1)
protein or peptide (1)
The First Affiliated Hospital of Xiamen University (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.